logo

Tag: SUPN

AMZN
Finance

Supernus Pharmaceuticals Inc (SUPN) Stock: Navigating a Year of Volatility

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Supernus Pharmaceuticals Inc’s current trading price is -23.63% away from its 52-week high, while its distance from the 52-week low is 20.49%.
Stock Investing

Be ready for liftoff for Supernus Pharmaceuticals Inc. (SUPN)

Qelbree, a drug developed by Supernus Pharmaceuticals, Inc. (SUPN), recently received FDA approval. Consequently, SUPN shares traded at 30.11 USD on April 5th for a gain of 12.7%. Qelbree is specifically approved to treat attention deficit hyperactivity disorder in patients between the ages of 6

Investchronicle.com is an Economic news website, which offers broad information about the Stock markets and Equities. The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis.
Facebook-f Twitter Google-plus-g Pinterest

Quick Links

Categories

All rights reserved © 2024, Powered By Smart TechOne

Invest Chronicle
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.